A Comprehensive Investigation of Associations Between Cell Death Pathways and Molecular and Clinical Features in Pan-cancer

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2024 Nov 2

PMID 39487950

Authors

Yin He

Xiaosheng Wang

Affiliations

Soon will be listed here.

Abstract

Background: Regulated cell death (RCD) pathways play significant roles in tumorigenesis. However, systematic investigation into correlations between RCD and various molecular and clinical features, particularly anti-tumor immunity and immunotherapy response in pan-cancer remains lacking.

Methods: Using the single-sample gene set enrichment analysis, we quantified the activities of six RCD pathways (apoptosis, autophagy, ferroptosis, cuproptosis, necroptosis, and pyroptosis) in each cancer specimen. Then, we explored associations of these six RCD pathways with tumor immunity, genomic instability, tumor phenotypes and clinical features, and responses to immunotherapy and targeted therapies in pan-cancer by statistical analyses.

Results: Our results showed that the RCD (except autophagy) activities were oncogenic signatures, as evidenced by their hyperactivation in late stage or metastatic cancer patients, positive correlations with tumor proliferation, stemness, genomic instability and intratumor heterogeneity, and correlation with worse survival outcomes in cancer. In contrast, autophagy was a tumor suppressive signature as its associations with molecular and clinical features in cancer shows an opposite pattern compared to the other RCD pathways. Furthermore, heightened RCD (except cuproptosis) activities were correlated with increased sensitivity to immune checkpoint inhibitors. Additionally, elevated activities of pyroptosis, autophagy, cuproptosis and necroptosis were associated with increased drug sensitivity in a broad spectrum of anti-tumor targeted therapies, while the elevated activity of ferroptosis was correlated with decreased sensitivity to numerous targeted therapies.

Conclusion: RCD (except autophagy) activities correlate with unfavorable cancer prognosis, while the autophagy activity correlate with favorable clinical outcomes. RCD (except cuproptosis) activities are positive biomarkers for anti-tumor immunity and immunotherapy response.

References

Yang F, Markovic S, Molina J, Halfdanarson T, Pagliaro L, Chintakuntlawar A . Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020; 3(8):e2012534. PMC: 7414387. DOI: 10.1001/jamanetworkopen.2020.12534. View

Ribas A, Wolchok J . Cancer immunotherapy using checkpoint blockade. Science. 2018; 359(6382):1350-1355. PMC: 7391259. DOI: 10.1126/science.aar4060. View

Carretero-Gonzalez A, Lora D, Ghanem I, Zugazagoitia J, Castellano D, Sepulveda J . Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. Oncotarget. 2018; 9(9):8706-8715. PMC: 5823578. DOI: 10.18632/oncotarget.24283. View

Darvin P, Toor S, Sasidharan Nair V, Elkord E . Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018; 50(12):1-11. PMC: 6292890. DOI: 10.1038/s12276-018-0191-1. View

Doroshow D, Bhalla S, Beasley M, Sholl L, Kerr K, Gnjatic S . PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021; 18(6):345-362. DOI: 10.1038/s41571-021-00473-5. View

Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope F . Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discov. 2020; 10(12):1808-1825. PMC: 7710563. DOI: 10.1158/2159-8290.CD-20-0522. View

Lemery S, Keegan P, Pazdur R . First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. N Engl J Med. 2017; 377(15):1409-1412. DOI: 10.1056/NEJMp1709968. View

Jiang Z, Liu Z, Li M, Chen C, Wang X . Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment. EBioMedicine. 2019; 42:431-442. PMC: 6491961. DOI: 10.1016/j.ebiom.2019.03.068. View

Goel S, DeCristo M, Watt A, BrinJones H, Sceneay J, Li B . CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017; 548(7668):471-475. PMC: 5570667. DOI: 10.1038/nature23465. View

10.

Chen Z, Chen C, Li L, Zhang T, Wang X . The spliceosome pathway activity correlates with reduced anti-tumor immunity and immunotherapy response, and unfavorable clinical outcomes in pan-cancer. Comput Struct Biotechnol J. 2021; 19:5428-5442. PMC: 8501672. DOI: 10.1016/j.csbj.2021.09.029. View

11.

Van Gool I, Eggink F, Freeman-Mills L, Stelloo E, Marchi E, de Bruyn M . POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clin Cancer Res. 2015; 21(14):3347-3355. PMC: 4627582. DOI: 10.1158/1078-0432.CCR-15-0057. View

12.

Zhang K, Hong X, Song Z, Xu Y, Li C, Wang G . Identification of Deleterious Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC. Clin Cancer Res. 2020; 26(14):3649-3661. DOI: 10.1158/1078-0432.CCR-19-3976. View

13.

Lu M, Zhao B, Liu M, Wu L, Li Y, Zhai Y . Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy. NPJ Precis Oncol. 2021; 5(1):51. PMC: 8203790. DOI: 10.1038/s41698-021-00193-0. View

14.

Li M, Ma Y, Zhong Y, Liu Q, Chen C, Qiang L . mutations promote antitumor immunity and immunotherapy response in cancer. J Immunother Cancer. 2020; 8(2). PMC: 7549479. DOI: 10.1136/jitc-2019-000293. View

15.

Li L, Li M, Jiang Z, Wang X . Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer. Cells. 2019; 8(7). PMC: 6678467. DOI: 10.3390/cells8070678. View

16.

Zhang Z, Li L, Li M, Wang X . The SARS-CoV-2 host cell receptor ACE2 correlates positively with immunotherapy response and is a potential protective factor for cancer progression. Comput Struct Biotechnol J. 2020; 18:2438-2444. PMC: 7462778. DOI: 10.1016/j.csbj.2020.08.024. View

17.

Ott P, Hodi F, Kaufman H, Wigginton J, Wolchok J . Combination immunotherapy: a road map. J Immunother Cancer. 2017; 5:16. PMC: 5319100. DOI: 10.1186/s40425-017-0218-5. View

18.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Rutkowski P, Lao C . Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019; 381(16):1535-1546. DOI: 10.1056/NEJMoa1910836. View

19.

Luo Q, Zhang L, Luo C, Jiang M . Emerging strategies in cancer therapy combining chemotherapy with immunotherapy. Cancer Lett. 2019; 454:191-203. DOI: 10.1016/j.canlet.2019.04.017. View

20.

Formenti S, Demaria S . Future of Radiation and Immunotherapy. Int J Radiat Oncol Biol Phys. 2020; 108(1):3-5. DOI: 10.1016/j.ijrobp.2020.04.034. View